Novavax (MEX:NVAX) Other Financing: MXN702 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVAX Novavax Inc MEX:NVAX
44 GF Score
Price MXN132.00
GF Value MXN56.72
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Other Financing?

Novavax MEX:NVAX 44 Other Financing is MXN702 Mil as of Jun. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 44/100 and a GF Value™ of MXN56.72 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novavax's Other Financing for the three months ended in Jun. 2026 was MXN840 Mil.

Novavax's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was MXN702 Mil.

Novavax Other Financing Historical Data

* Premium members only.

The historical data trend for Novavax's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Other Financing Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 507.95 -114.97 -58.26 27.22 -86.39

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.06 15.04 -5.94 -147.11 839.96
MEX:NVAX
44GF Score
Novavax Inc MEX:NVAX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN702 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of MXN702 Mil mean?
Novavax (MEX:NVAX) has a Other Financing of MXN702 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Novavax and its competitors.
Is Novavax's Other Financing too high?
Novavax's current Other Financing is MXN702 Mil. Overall, Novavax has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Other Financing compare to JBIO and AVLN?
Novavax's Other Financing of MXN702 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Novavax and its competitors. Novavax's current Other Financing is MXN702 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN56.72, compared to a current price of MXN132.00 — trading 132.7% above its estimated fair value. The current Other Financing is MXN702 Mil. Novavax's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Other Financing is MXN702 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN132.00 is trading 132.7% above its estimated GF Value™ of MXN56.72. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Other Financing: MXN702 Mil
  • GF Value™: MXN56.72 vs. price of MXN132.00 (132.7% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
44GF Score

Get the complete analysis for MEX:NVAX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN132.00
Price
MXN56.72
GF Value